48,453
edits
Difference between revisions of "ROS1-rearranged non-small cell lung carcinoma"
Jump to navigation
Jump to search
ROS1-rearranged non-small cell lung carcinoma (view source)
Revision as of 02:18, 31 December 2019
, 02:18, 31 December 2019no edit summary
(create) |
|||
| Line 1: | Line 1: | ||
'''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK | '''ROS1-rearranged non-small cell lung carcinoma''' is a subtype of [[non-small cell lung carcinoma]] that can be treated with [[ALK inhibitors]].<ref name=pmid25264305>{{Cite journal | last1 = Shaw | first1 = AT. | last2 = Ou | first2 = SH. | last3 = Bang | first3 = YJ. | last4 = Camidge | first4 = DR. | last5 = Solomon | first5 = BJ. | last6 = Salgia | first6 = R. | last7 = Riely | first7 = GJ. | last8 = Varella-Garcia | first8 = M. | last9 = Shapiro | first9 = GI. | title = Crizotinib in ROS1-rearranged non-small-cell lung cancer. | journal = N Engl J Med | volume = 371 | issue = 21 | pages = 1963-71 | month = Nov | year = 2014 | doi = 10.1056/NEJMoa1406766 | PMID = 25264305 }}</ref> | ||
==General== | |||
*ROS1-rearrangements are seen in approximately 1-2% of [[non-small cell carcinoma]].<ref name=pmid31720561>{{cite journal |vauthors=Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW |title=Targeted therapies for ROS1-rearranged non-small cell lung cancer |journal=Drugs Today |volume=55 |issue=10 |pages=641–652 |date=October 2019 |pmid=31720561 |doi=10.1358/dot.2019.55.10.3030646 |url=}}</ref> | |||
==See also== | ==See also== | ||